Navigation Links
Benda Pharmaceutical Announces Resignation of Board Member
Date:6/19/2008

HUBEI PROVINCE, China, June 19 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today announced that Charles Mo has resigned from the Board of Directors of Benda Pharmaceutical, Inc., effective June 15, 2008. Mr. Mo joined the Board in 2007 and served as an independent director as well as Chairman of the Audit Committee.

"On behalf of the board of directors and management team, I would like to thank Mr. Mo for his many contributions and dedicated service to the Company. His leadership and vision have been invaluable to the Company and we wish him well in his future endeavors," said Charles Wan, Chief Executive Officer of Benda Pharmaceutical. "Meanwhile, the Board is conducting a thorough replacement search."

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.

Safe Harbor Statement

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.


'/>"/>
SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Benda Pharmaceutical Reports First Quarter 2008 Financial Results
2. Benda Pharmaceutical Appoints Jun Tang to Board of Directors
3. Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
4. HighPoint Solutions Signs Deal to Implement Model N Managed Care and Government Pricing System for Specialty Pharmaceutical Company
5. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
6. Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC
7. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
8. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
9. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
10. Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
11. Worldwide Pharmaceutical Industry, Aid Organizations Warn of Second Disaster in Myanmar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 28, 2016 , ... "Color Grading media can be time consuming but with ... media," said Christina Austin - CEO of Pixel Film Studios. , With the ... stylish color grades to their footage. A LUT is a Lookup Table that contains ...
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log Home™, ... found on its website at SouthlandLogHomes.com. , The designs of the wood barn ... of timber post and beam construction. The result is a barn that not ...
(Date:5/27/2016)... ... 27, 2016 , ... This campaign aims to provide a path to improved ... can control and change. , As nearly 795,000 Americans suffering from a new or ... States. Plus, with an estimated 129,000 of these people dying from stroke, it’s become ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... ... 2016 , ... W.S. Badger Co. Inc ., the maker of certified ... Work Works Award for its use of effective workplace strategies to increase business and ... administered by the Families and Work Institute (FWI) and the Society for Human Resource ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... focused on advancing renal care, today announced that ... participate in the following schedule of investor conferences. Where ... available at http://ir.nxstage.com/ .   ... Healthcare Conference NY, NY           Friday, June 10, 2016 ...
(Date:5/24/2016)... -- The innovator of COMBO ... s first dual therapy stent, introduces catheters for lower ... a global company specializing in the provision of life-changing ... to treat peripheral artery disease. The JADE™ and Scoreflex™ ... lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... England , May 24, 2016 ... and Education in Clinical Neurophysiology  Elsevier ... information products and services, today announced the launch of ... an open access journal that focuses on clinical practice ... research, case reports, clinical series, normal values and didactic ...
Breaking Medicine Technology: